1. Home
  2. HBB vs DCTH Comparison

HBB vs DCTH Comparison

Compare HBB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$16.75

Market Cap

217.9M

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.15

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
DCTH
Founded
1904
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
217.9M
350.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
HBB
DCTH
Price
$16.75
$10.15
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$22.60
AVG Volume (30 Days)
30.8K
508.5K
Earning Date
11-05-2025
11-04-2025
Dividend Yield
2.91%
N/A
EPS Growth
24.53
N/A
EPS
2.34
0.03
Revenue
$607,430,000.00
$79,603,000.00
Revenue This Year
N/A
$131.69
Revenue Next Year
N/A
$39.22
P/E Ratio
$7.06
$294.73
Revenue Growth
N/A
251.54
52 Week Low
$12.72
$8.12
52 Week High
$21.20
$18.23

Technical Indicators

Market Signals
Indicator
HBB
DCTH
Relative Strength Index (RSI) 54.30 55.82
Support Level $15.62 $9.98
Resistance Level $17.23 $10.37
Average True Range (ATR) 0.75 0.39
MACD -0.07 0.01
Stochastic Oscillator 52.77 49.00

Price Performance

Historical Comparison
HBB
DCTH

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: